Olaparib is a drug with the potential to extend the lives of hundreds of prostate cancer patients, specifically those men with the BRCA gene mutation who have stopped responding to abiraterone. NICE have now approved this for use on the NHS, in what is seen as an important precedent for the use of targeted treatment of this kind. Credit: prostatecanceruk.org